Nephrology · Glomerular DiseaseNephrology · Sakit sa GlomerulusNephrology · Sakit sa GlomerulusNephrology · Sakit king Glomerulus

Nephritic Syndrome: Recognize It, Act Fast, Find the CauseNephritic Syndrome: Kilalanin, Kumilos Agad, Hanapin ang SanhiNephritic Syndrome: Ilha, Lihok Dayon, Pangitaa ang HinungdanNephritic Syndrome: Kilalanan, Kumilus Agad, Pantunan ing Sanhi

Primer: Nephritic Syndromes

Blood or protein in the urine, swelling, and rising blood pressure can mean the kidney’s filters are inflamed. Here is how to spot a kidney emergency, what tests to expect, and how doctors find the cause.Ang dugo o protina sa ihi, pamamaga, at tumataas na presyon ay maaaring mangahulugang namamaga ang mga salaan ng bato. Narito kung paano makilala ang emergency sa bato, anong mga pagsusuri ang aasahan, at paano hinahanap ng doktor ang sanhi.Ang dugo o protina sa ihi, panghubag, ug nagsaka nga presyon mahimong nagpasabot nga nanghubag ang mga salaan sa kidney. Ania kung unsaon pag-ila sa emergency sa kidney, unsang mga pagsusi ang gilauman, ug unsaon pagpangita sa doktor sa hinungdan.Ing daya o protina king ume, pamamaga, ampo mamuntuk a presyun malyari yang kayulugan a mamaga la reng salaan ning bató. Oyni nung makananu mu kilalanan ing emergency king bató, nanung pamanyuri ing iasa, at makananu pantunan ning doktor ing sanhi.

Recognize the pattern, act on tempo, and narrow the cause: first-hours escalation, serology and biopsy strategy, cause-specific management, and 2026 evidence.

Summary

Diagnosis. Nephritic syndrome is a pattern of glomerular hematuria with variable proteinuria, hypertension, edema, and falling glomerular filtration rate (GFR); rapidly progressive glomerulonephritis (RPGN) is a tempo and crescents are a lesion. Acanthocytes or red cell casts support, but cannot exclude, a glomerular source.

Practice. Escalate emergencies without waiting for serology. Send C3/C4 and, in RPGN, anti-glomerular basement membrane (anti-GBM) and antineutrophil cytoplasmic antibody (ANCA) tests together; exclude infection; biopsy when it changes management.

Evidence. Plasma exchange did not reduce death or kidney failure in PEXIVAS. Three 2026 immunoglobulin A (IgA) nephropathy trials slowed estimated GFR loss over two years. ADVOCATE (avacopan) was retracted.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 33 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
Last ReviewedHuling Na-reviewKatapusang Na-reviewKarinan Na-review:
A Filipino mother in her thirties sitting with her school-age son in a bright clinic as a kind physician holds up a clear urine sample cup and points to a simple kidney model on the desk, the family listening attentively.

Inflamed kidney filters: what “nephritic” meansNamamagang salaan ng bato: ano ang ibig sabihin ng “nephritic”Nanghubag nga salaan sa kidney: unsa ang buot ipasabot sa “nephritic”Mamagang salaan ning bató: nanu ing kayulugan ning “nephritic”

Your kidneys have about two million tiny filters called glomeruli. When these filters become inflamed, blood and protein leak into the urine. Your urine may look like tea or cola, or it may look normal. Some people develop puffy eyelids or ankles, high blood pressure, or pass much less urine. Doctors call this pattern nephritic syndrome. It is a warning sign, not a final diagnosis: a urine test and blood tests show whether the filters are involved, and further tests find the cause.May humigit-kumulang dalawang milyong maliliit na salaan ang iyong bato na tinatawag na glomeruli. Kapag namaga ang mga salaang ito, tumatagas ang dugo at protina sa ihi. Maaaring magmukhang tsaa o cola ang ihi mo, o maaaring mukhang normal. May ilang namamaga ang talukap ng mata o bukung-bukong, tumataas ang presyon, o kumokonti ang ihi. Tinatawag ito ng mga doktor na nephritic syndrome. Babala ito, hindi pa huling diagnosis: makikita sa pagsusuri ng ihi at dugo kung apektado ang mga salaan, at hahanapin ng iba pang pagsusuri ang sanhi.Ang imong kidney adunay mga duha ka milyon nga gagmayng salaan nga gitawag og glomeruli. Kung manghubag kini nga mga salaan, mogawas ang dugo ug protina sa ihi. Mahimong murag tsa o cola ang imong ihi, o mahimong murag normal. Ang uban manghubag ang tabon sa mata o buolbuol, mosaka ang presyon, o mogamay ang ihi. Gitawag kini sa mga doktor og nephritic syndrome. Pasidaan kini, dili pa katapusang diagnosis: makita sa pagsusi sa ihi ug dugo kung apektado ang mga salaan, ug pangitaon sa ubang pagsusi ang hinungdan.Atin lang adwang milyun a malati a salaan ing bató mu, aus deng glomeruli. Nung mamaga la reni, tutulu ya ing daya ampo protina king ume. Malyari yang anti tsaa o cola ing ume mu, o malyari yang anti normal. Atin kareng mamaga ing pikit mata o bukung-bukung, mamuntuk ing presyun, o mekaunti ing ume. Aus de reng doktor iti a nephritic syndrome. Babala ya iti, ali ya pa ing tutung diagnosis: ing pamanyuri king ume ampo daya ing mamakit nung apektadu la reng salaan, at ing aliwa pang pamanyuri ing manintun king sanhi.

How a healthy filter works. Each glomerulus is a ball of very thin blood vessels wrapped in a three-layer wall. That wall is a precise sieve: water, salt, and small wastes pass through into the urine, while red blood cells and the large protein albumin stay in the blood. Think of it like a fine coffee filter that lets the coffee through but keeps the grounds back.Paano gumagana ang malusog na salaan. Ang bawat glomerulus ay bola ng napakanipis na ugat na binabalot ng pader na may tatlong patong. Eksaktong salaan ang pader na iyon: dumadaan sa ihi ang tubig, asin, at maliliit na dumi, habang nananatili sa dugo ang mga red blood cell at ang malaking protinang albumin. Parang pinong salaan ng kape na nagpapadaan sa kape pero pinipigil ang latak.Unsaon pagtrabaho sa himsog nga salaan. Ang matag glomerulus usa ka bola sa nipis kaayong ugat nga giputos sa bungbong nga adunay tulo ka sapaw. Eksakto nga salaan kana nga bungbong: moagi sa ihi ang tubig, asin, ug gagmayng hugaw, samtang magpabilin sa dugo ang mga red blood cell ug ang dakong protina nga albumin. Sama kini sa pinong salaan sa kape nga mopaagi sa kape apan mopugong sa lapok.Makananu ya gagana ing malusug a salaan. Ing balang glomerulus metung yang bola da reng manipis a ugat a balut ning pader a atlung patung. Eksaktung salaan ya ing pader a ita: dumalan king ume ing danum, asin, ampo malati a dinat, kabang mananatili king daya deng red blood cell ampo ing maragul a protina a albumin. Anti ya salaan ning kape a pasalan na ing kape dapot pigilan na ing latak.

What inflammation does. In nephritic syndrome, the immune system attacks the filter or dumps immune clumps into it. The inflamed wall develops tiny tears, and red blood cells squeeze through. As they push through the gaps, many come out bent and misshapen, and some get packed together into tube-shaped “casts” in the kidney’s drainage pipes. Finding these misshapen cells and casts under the microscope tells the doctor the bleeding is coming from the filters, not from the bladder or a stone. The coffee-filter picture has limits: a real filter wall is living tissue, so the swelling also slows filtering, and the kidney holds on to salt and water. That is why blood pressure rises and the face and ankles swell.Ano ang ginagawa ng pamamaga. Sa nephritic syndrome, inaatake ng immune system ang salaan o nagtatambak dito ng mga kumpol ng immune complex. Nagkakaroon ng maliliit na punit ang namamagang pader, at sumisiksik palabas ang mga red blood cell. Habang dumadaan sa mga puwang, marami ang lumalabas na baluktot at sira ang hugis, at ang ilan ay nagsisiksikan sa hugis-tubong “cast” sa mga daluyan ng bato. Kapag nakita sa mikroskopyo ang mga sirang selulang ito at mga cast, alam ng doktor na galing sa mga salaan ang pagdurugo, hindi sa pantog o bato sa daanan ng ihi. May hangganan ang paghahambing sa salaan ng kape: buhay na tisyu ang tunay na pader, kaya bumabagal din ang pagsasala at kumakapit ang bato sa asin at tubig. Kaya tumataas ang presyon at namamaga ang mukha at bukung-bukong.Unsa ang buhaton sa panghubag. Sa nephritic syndrome, atakehon sa immune system ang salaan o tapokan kini og mga pundok sa immune complex. Magkaroon og gagmayng gisi ang nanghubag nga bungbong, ug mosiksik pagawas ang mga red blood cell. Samtang moagi sa mga lusot, daghan ang mogawas nga baliko ug guba ang porma, ug ang uban magpundok sa porma-tubo nga “cast” sa mga agianan sa kidney. Kung makita sa mikroskopyo kining gubang mga selula ug cast, mahibal-an sa doktor nga gikan sa salaan ang pagdugo, dili sa pantog o bato sa agianan sa ihi. Adunay utlanan ang pagtandi sa salaan sa kape: buhi nga tisyu ang tinuod nga bungbong, mao nga mohinay usab ang pagsala ug kuptan sa kidney ang asin ug tubig. Mao nga mosaka ang presyon ug manghubag ang nawong ug buolbuol.Nanu ing gagawan ning pamamaga. King nephritic syndrome, atakian ning immune system ing salaan o tambakan de reng kumpul ning immune complex. Mika malati a pirasu (tears) ing mamagang pader, at sisiksik la palwal deng red blood cell. Kabang dadalan la king lugal, dakal ing lumual a baluktut at sira ing itsura, at deng aliwa misiksik la king anyung-tubu a “cast” kareng daluyan ning bató. Nung akit la king mikroskopyo reng siran selula ampo cast, abalu ning doktor a ibat la king salaan ing pamagdaya, ali king pantug o batu king dalan ning ume. Atin ya anggan ing pamanibatan king salaan ning kape: mabie yang tisyu ing tune a pader, kaya kumupad ing pamanyalaan at kakaptan ning bató ing asin ampo danum. Ita ing sanhi nung bakit mamuntuk ing presyun at mamaga ing lupa ampo bukung-bukung.

Two side-by-side magnified kidney filters. On the left a healthy glomerulus keeps round red blood cells and albumin inside the blood vessels while clear fluid passes into the urine space. On the right an inflamed glomerulus with swollen walls and immune cells lets red blood cells squeeze through small gaps, coming out misshapen, with a few packed into a tube-shaped cast below.

Left: a healthy filter keeps red blood cells and protein in the blood. Right: an inflamed filter lets red blood cells squeeze through; they come out misshapen and can pack into tube-shaped casts.Kaliwa: pinapanatili ng malusog na salaan ang red blood cell at protina sa dugo. Kanan: pinapadaan ng namamagang salaan ang red blood cell; lumalabas silang sira ang hugis at maaaring magsiksikan sa hugis-tubong cast.Wala: gitipigan sa himsog nga salaan ang red blood cell ug protina sa dugo. Tuo: gipaagi sa nanghubag nga salaan ang red blood cell; mogawas sila nga guba ang porma ug mahimong magpundok sa porma-tubo nga cast.Kayli: pananatilan ning malusug a salaan deng red blood cell ampo protina king daya. Wanan: pasalan na ning mamagang salaan deng red blood cell; lumual lang sira ing itsura at malyari lang misiksik king anyung-tubu a cast.

RBC
Red blood cell

What you might notice — and what you might notAno ang maaari mong mapansin — at ano ang maaaring hindiUnsa ang mahimo nimong mamatikdan — ug unsa ang diliNanu ing malyari mung apansinan — at nanu ing ali

Nephritic syndrome can arrive suddenly over days or creep in over weeks. The full set of signs does not need to be present, and some people feel completely well. Common clues:Maaaring biglang dumating ang nephritic syndrome sa loob ng ilang araw o dahan-dahan sa loob ng ilang linggo. Hindi kailangang naroon ang lahat ng palatandaan, at may ilang tao na ganap na maganda ang pakiramdam. Karaniwang palatandaan:Mahimong kalit moabot ang nephritic syndrome sulod sa pipila ka adlaw o hinay-hinay sulod sa pipila ka semana. Dili kinahanglang naa ang tanang timailhan, ug ang uban bug-os nga maayo ang pamati. Kasagarang timailhan:Malyari yang biglang dumatang ing nephritic syndrome king lalam da reng aldo o malumanayan king lalam da reng dominggu. E kailangan a atiu la ngan deng tanda, at atin kareng tau a mayap ing pamakiramdam. Karaniwan a tanda:

Nephritic or nephrotic? Two different leaksNephritic o nephrotic? Dalawang magkaibang tagasNephritic o nephrotic? Duha ka lahing tuloNephritic o nephrotic? Adwang magkaibang tulu

The names sound alike but describe different filter problems. In nephritic disease the filter is inflamed and bleeds. In nephrotic disease the filter leaks large amounts of protein with little inflammation, causing heavy swelling. Some illnesses show features of both.Magkatunog ang pangalan pero magkaibang problema sa salaan ang tinutukoy. Sa sakit na nephritic, namamaga at dumudugo ang salaan. Sa sakit na nephrotic, tumatagas ang napakaraming protina na may kaunting pamamaga, kaya matindi ang pamamaga ng katawan. May mga sakit na may katangian ng dalawa.Managsama ang tunog sa ngalan apan lahi nga problema sa salaan ang gipasabot. Sa sakit nga nephritic, nanghubag ug nagdugo ang salaan. Sa sakit nga nephrotic, daghan kaayong protina ang mogawas nga gamay ra ang panghubag sa salaan, mao nga grabe ang panghubag sa lawas. Adunay mga sakit nga naay kinaiya sa duha.Magkatunug la reng lagyu dapot magkaibang problema king salaan ing tutukuyan da. King sakit a nephritic, mamaga at magdaya ing salaan. King sakit a nephrotic, dakal a protina ing tutulu a mekaunting pamamaga ning salaan, kaya marine ing pamamaga ning katawan. Atin sakit a atin katangian ning adwa.

FeatureKatangianKinaiyaKatangianNephriticNephrotic
Main leakPangunahing tagasPangunang tuloPangunang tuluBlood, with some proteinDugo, may kaunting protinaDugo, uban ang pipila ka protinaDaya, atin mekaunting protinaLarge amounts of proteinNapakaraming protinaDaghan kaayong protinaDakal a protina
UrineIhiIhiUmeTea- or cola-colored, or normal-lookingKulay-tsaa o cola, o mukhang normalKolor-tsa o cola, o murag normalKulay-tsaa o cola, o anti normalVery foamyNapakabulaBulahon kaayoMabula ya
Blood pressurePresyonPresyonPresyunOften highMadalas mataasKasagaran taasMalagad matasNormal or highNormal o mataasNormal o taasNormal o matas
Kidney functionPaggana ng batoPaglihok sa kidneyPamagobra ning batóCan fall quicklyMaaaring bumaba nang mabilisMahimong mokunhod dayonMalyari yang mababa agadOften normal at firstMadalas normal sa simulaKasagaran normal sa sinugdananMalagad normal king umpisa
SwellingPamamagaPanghubagPamamagaMild to moderateBahagya hanggang katamtamanGamay hangtod kasaranganMekaunti angga katamtamanOften markedMadalas matindiKasagaran grabeMalagad marine
Split-panel comparison. Left panel labeled nephritic: an inflamed glomerulus leaking red blood cells, a jar of tea-colored urine, a blood pressure cuff reading high, and mild ankle swelling. Right panel labeled nephrotic: a glomerulus leaking many protein particles with little inflammation, a jar of very foamy urine, and marked leg and eyelid swelling.

Nephritic (left) means an inflamed, bleeding filter with high blood pressure. Nephrotic (right) means heavy protein leak with marked swelling. Some diseases show both.Ang nephritic (kaliwa) ay namamaga at dumudugong salaan na may mataas na presyon. Ang nephrotic (kanan) ay matinding tagas ng protina na may matinding pamamaga. May sakit na nagpapakita ng dalawa.Ang nephritic (wala) nanghubag ug nagdugo nga salaan nga taas ang presyon. Ang nephrotic (tuo) grabe nga tulo sa protina nga grabe ang panghubag. Adunay sakit nga magpakita sa duha.Ing nephritic (kayli) mamaga at magdaya a salaan a matas ing presyun. Ing nephrotic (wanan) marine a tulu ning protina a marine ing pamamaga. Atin sakit a pakit na ing adwa.

Four large simple pictograms in a row on a white card with a red border: a person short of breath holding their chest, a person coughing with a small red droplet, a urine cup almost empty, and a person holding their head with swirl lines for confusion and blurred vision. Below them a hospital emergency sign with an arrow.

Go to the emergency room now for trouble breathing, coughing up blood, almost no urine, or a severe headache with confusion, vision changes, or a seizure.Pumunta agad sa emergency room kung hirap huminga, umuubo ng dugo, halos walang ihi, o matinding sakit ng ulo na may pagkalito, pagbabago sa paningin, o kombulsyon.Adto dayon sa emergency room kung lisod moginhawa, nag-ubo og dugo, halos walay ihi, o grabeng sakit sa ulo nga naay kalibog, kausaban sa panan-aw, o kombulsyon.Munta ka agad king emergency room nung mirap manyawa, kukuyu yang daya, mulala ala nang ume, o masakit a buntuk a atin kalitu, pamagbayu king pamanalakad, o kombulsyon.

Many causes, one patternMaraming sanhi, iisang patternDaghang hinungdan, usa ka patternDakal a sanhi, metung a pattern

Nephritic syndrome is a pattern that many different diseases can produce. Treatment depends entirely on the cause, which is why the tests matter. The most common causes in the Philippines and worldwide include:Ang nephritic syndrome ay pattern na maaaring idulot ng maraming iba't ibang sakit. Lubos na nakadepende sa sanhi ang gamutan, kaya mahalaga ang mga pagsusuri. Kabilang sa pinakakaraniwang sanhi sa Pilipinas at sa buong mundo:Ang nephritic syndrome usa ka pattern nga mahimong hinungdan sa daghang lain-laing sakit. Hingpit nga nagdepende sa hinungdan ang pagtambal, mao nga importante ang mga pagsusi. Lakip sa labing kasagarang hinungdan sa Pilipinas ug sa tibuok kalibutan:Ing nephritic syndrome metung yang pattern a malyari yang sanhian da reng dakal a magkaibang sakit. Makadepende ya ngan king sanhi ing panamuyut, kaya mayalaga la reng pamanyuri. Kayabe kareng pekakaraniwan a sanhi king Pilipinas at king sablang yatu:

🦠

After a throat or skin infectionPagkatapos ng impeksyon sa lalamunan o balatHuman sa impeksyon sa tutunlan o panitKaybat ning impeksyun king akmulan o balat

Post-streptococcal glomerulonephritis appears about 1–3 weeks after strep throat or infected skin sores, most often in children. Most children recover fully.Lumilitaw ang post-streptococcal glomerulonephritis mga 1–3 linggo pagkatapos ng strep throat o impeksyon sa sugat sa balat, kadalasan sa mga bata. Karamihan sa mga bata ay ganap na gumagaling.Mogawas ang post-streptococcal glomerulonephritis mga 1–3 ka semana human sa strep throat o impeksyon sa samad sa panit, kasagaran sa mga bata. Kadaghanan sa mga bata hingpit nga mamaayo.Lilitaw ya ing post-streptococcal glomerulonephritis 1–3 dominggu kaybat ning strep throat o impeksyun king sugat king balat, malagad kareng anak. Dakal kareng anak ing manyakit a tutu.

🤧

IgA nephropathyIgA nephropathyIgA nephropathyIgA nephropathy

IgA stands for immunoglobulin A, an antibody that gets stuck in the filters. Cola-colored urine during or right after a cold or sore throat. The most common filter inflammation worldwide, and common in Asia. It needs a biopsy to confirm.Ang IgA ay immunoglobulin A, isang antibody na naiipit sa mga salaan. Ihing kulay-cola habang o pagkatapos mismo ng sipon o sore throat. Pinakakaraniwang pamamaga ng salaan sa buong mundo, at karaniwan sa Asya. Kailangan ng biopsy para makumpirma.Ang IgA mao ang immunoglobulin A, usa ka antibody nga maipit sa mga salaan. Ihi nga kolor-cola samtang o human dayon sa sip-on o sore throat. Labing kasagarang panghubag sa salaan sa kalibutan, ug kasagaran sa Asya. Kinahanglan og biopsy aron makumpirma.Ing IgA iya ing immunoglobulin A, metung a antibody a maiipit kareng salaan. Ume a kulay-cola kabang o kaybat mismu ning sipun o sore throat. Pekakaraniwan a pamamaga ning salaan king yatu, at karaniwan king Asya. Kailangan ya ing biopsy ban akumpirma.

🦋

Lupus nephritisLupus nephritisLupus nephritisLupus nephritis

Lupus can inflame the kidney filters, often in young women, sometimes with rash, joint pains, or mouth sores.Maaaring pamagain ng lupus ang mga salaan ng bato, kadalasan sa mga batang babae, minsan may pantal, pananakit ng kasukasuan, o singaw.Mahimong panghubagon sa lupus ang mga salaan sa kidney, kasagaran sa batan-ong babaye, usahay uban ang bugas, sakit sa lutahan, o singaw.Malyari nang pamagan ning lupus deng salaan ning bató, malagad kareng bayung babai, misan atin pantal, masakit a kasukasuan, o singo.

🫁

Vasculitis and anti-GBM diseaseVasculitis at anti-GBM diseaseVasculitis ug anti-GBM diseaseVasculitis at anti-GBM disease

The immune system attacks small blood vessels (vasculitis) or the filter wall itself (anti-glomerular basement membrane disease). Kidney function can fall within days, sometimes with bleeding in the lungs. These are emergencies.Inaatake ng immune system ang maliliit na ugat (vasculitis) o mismong pader ng salaan (anti-glomerular basement membrane disease). Maaaring bumagsak ang paggana ng bato sa loob ng ilang araw, minsan may pagdurugo sa baga. Emergency ang mga ito.Atakehon sa immune system ang gagmayng ugat (vasculitis) o ang bungbong mismo sa salaan (anti-glomerular basement membrane disease). Mahimong mokunhod ang paglihok sa kidney sulod sa pipila ka adlaw, usahay uban ang pagdugo sa baga. Emergency kini.Atakian ning immune system deng malati a ugat (vasculitis) o ing pader mismu ning salaan (anti-glomerular basement membrane disease). Malyari yang mababa ing pamagobra ning bató king lalam da reng aldo, misan atin pamagdaya king baga. Emergency la reni.

❤️

Infections that are still activeImpeksyong aktibo paImpeksyon nga aktibo paImpeksyun a aktibu pa

In adults, an ongoing staph infection or an infected heart valve (endocarditis) can inflame the filters. Here the cure is treating the infection, not suppressing the immune system.Sa matatanda, maaaring pamagain ang mga salaan ng patuloy na impeksyong staph o impeksyon sa balbula ng puso (endocarditis). Dito, ang lunas ay gamutin ang impeksyon, hindi pahinain ang immune system.Sa mga hamtong, mahimong panghubagon ang mga salaan sa nagpadayong impeksyon sa staph o impeksyon sa balbula sa kasingkasing (endocarditis). Dinhi, ang tambal mao ang pagtambal sa impeksyon, dili ang pagpaluya sa immune system.Kareng matua, malyari nang pamagan deng salaan ning tuluy-tuluy a impeksyun a staph o impeksyun king balbula ning pusu (endocarditis). Keni, ing lunas iyang gamutan ing impeksyun, ali pakapuyan ing immune system.

🧬

Complement and other rarer causesComplement at iba pang bihirang sanhiComplement ug ubang talagsaong hinungdanComplement at aliwa pang bihirang sanhi

Overactive complement (a part of the immune system), hepatitis-related cryoglobulins, and inherited filter-wall conditions are less common causes that specialists look for.Ang sobrang aktibong complement (bahagi ng immune system), cryoglobulin na kaugnay ng hepatitis, at minanang kondisyon ng pader ng salaan ay hindi gaanong karaniwang sanhi na hinahanap ng mga espesyalista.Ang sobrang aktibo nga complement (bahin sa immune system), cryoglobulin nga may kalabutan sa hepatitis, ug napanunod nga kondisyon sa bungbong sa salaan mga dili kaayo kasagarang hinungdan nga pangitaon sa mga espesyalista.Ing sobrang aktibu a complement (bage ning immune system), cryoglobulin a misasaup king hepatitis, ampo mamanang kundisyun ning pader ning salaan, la reng e masyadung karaniwan a sanhi a pantunan da reng espesyalista.

A single kidney filter drawn in the center of a white page, slightly inflamed, with six simple labeled pathways around it: a sore throat and skin sore, a runny nose with an IgA antibody shape, a butterfly for lupus, small blood vessels with immune cells for vasculitis, a heart valve for infection, and a gene strand for complement and rare causes.

One pattern, many causes: infections, IgA, lupus, vasculitis, an infected heart valve, and complement problems can all inflame the filters. Finding which one decides the treatment.Iisang pattern, maraming sanhi: impeksyon, IgA, lupus, vasculitis, impeksyon sa balbula ng puso, at problema sa complement ay maaaring magpamaga sa mga salaan. Ang paghahanap kung alin ang nagpapasya ng gamutan.Usa ka pattern, daghang hinungdan: impeksyon, IgA, lupus, vasculitis, impeksyon sa balbula sa kasingkasing, ug problema sa complement mahimong mopahubag sa mga salaan. Ang pagpangita kung asa ang modesisyon sa pagtambal.Metung a pattern, dakal a sanhi: impeksyun, IgA, lupus, vasculitis, impeksyun king balbula ning pusu, ampo problema king complement malyari lang pamagan deng salaan. Ing pamanintun nung nanu kareni ing mamagpasya king panamuyut.

IgA
Immunoglobulin A

What the team will checkAno ang susuriin ng teamUnsa ang susihon sa teamNanu ing surian ning team

The first job is to see how fast things are moving. The team checks your blood pressure, oxygen, and how much urine you pass, then compares today’s kidney blood test (creatinine) with any older results. Bring every past lab result you have; an old result can show whether a change is new.Ang unang trabaho ay alamin kung gaano kabilis ang pagbabago. Susuriin ng team ang iyong presyon, oxygen, at dami ng ihi, saka ihahambing ang kidney blood test ngayon (creatinine) sa mga lumang resulta. Dalhin ang lahat ng dati mong lab result; maipapakita ng lumang resulta kung bago ang pagbabago.Ang unang trabaho mao ang pagtan-aw kung unsa ka paspas ang pagbag-o. Susihon sa team ang imong presyon, oxygen, ug gidaghanon sa ihi, unya itandi ang kidney blood test karon (creatinine) sa bisan unsang daang resulta. Dad-a ang tanan nimong kanhing lab result; ikapakita sa daang resulta kung bag-o ba ang pagbag-o.Ing mumunang obra iyang balu nung makananu kabilis ing pamagbayu. Surian ning team ing presyun mu, oxygen, ampo nung pilan ing ume mu, kaybat ibandingan ing kidney blood test ngeni (creatinine) kareng lumang resulta. Darun mu ngan deng dating lab result mu; apakit ning lumang resulta nung bayu ya ing pamagbayu.

The usual first testsAng karaniwang unang pagsusuriAng naandang unang pagsusiDeng karaniwang mumunang pamanyuri
1
Fresh urine test with microscope check — looks for misshapen red cells and casts that point to the filters, and measures protein.Pagsusuri ng sariwang ihi na may mikroskopyo — hinahanap ang mga sirang red cell at cast na tumuturo sa mga salaan, at sinusukat ang protina.Pagsusi sa presko nga ihi nga adunay mikroskopyo — pangitaon ang gubang red cell ug cast nga nagtudlo sa mga salaan, ug sukdon ang protina.Pamanyuri king sariwang ume a atin mikroskopyu — pantunan deng siran red cell ampo cast a tuturu kareng salaan, at sukatan ing protina.
2
Blood tests — creatinine and potassium, blood count, albumin, and immune tests such as complement (C3, C4) and antibodies (ANCA, anti-GBM, ANA). Infection tests may be added.Pagsusuri ng dugo — creatinine at potassium, blood count, albumin, at immune test gaya ng complement (C3, C4) at antibody (ANCA, anti-GBM, ANA). Maaaring idagdag ang pagsusuri sa impeksyon.Pagsusi sa dugo — creatinine ug potassium, blood count, albumin, ug immune test sama sa complement (C3, C4) ug antibody (ANCA, anti-GBM, ANA). Mahimong idugang ang pagsusi sa impeksyon.Pamanyuri king daya — creatinine ampo potassium, blood count, albumin, ampo immune test anti ning complement (C3, C4) ampo antibody (ANCA, anti-GBM, ANA). Malyari dang idagdag ing pamanyuri king impeksyun.
3
Kidney ultrasound — checks size and rules out blockage. It does not show inflammation.Ultrasound ng bato — sinusuri ang laki at inaalis ang posibilidad ng bara. Hindi nito nakikita ang pamamaga.Ultrasound sa kidney — susihon ang gidak-on ug isalikway ang posibilidad sa bara. Dili kini makakita sa panghubag.Ultrasound ning bató — surian ing kayaraga at alisan ing posibilidad ning bara. Ali na akakit ing pamamaga.
4
Kidney biopsy — when needed, a thin needle takes a tiny piece of kidney for the pathologist. It shows the type of inflammation and how much is still treatable versus already scarred.Kidney biopsy — kapag kailangan, kumukuha ang manipis na karayom ng maliit na piraso ng bato para sa pathologist. Ipinapakita nito ang uri ng pamamaga at kung gaano karami ang magagamot pa kumpara sa peklat na.Kidney biopsy — kung kinahanglan, mokuha ang nipis nga dagom og gamayng piraso sa kidney para sa pathologist. Ipakita niini ang klase sa panghubag ug kung pila pa ang matambalan kumpara sa nagpeklat na.Kidney biopsy — nung kailangan, mangua ya ing manipis a dagum ning malating pirasu ning bató para king pathologist. Pakit na nung nanung klasi ing pamamaga at nung pilan pa ing agamutan kumpara kareng mepeklat na.
💡

A normal-looking test does not end the searchHindi tapos ang paghahanap kahit mukhang normal ang pagsusuriDili mahuman ang pagpangita bisan murag normal ang pagsusiAli mapupus ing pamanintun agyang anti normal ing pamanyuri

No single test rules out serious filter inflammation. Antibody tests can be negative, and the microscope can miss misshapen cells. If your kidney function is falling, the team acts on the whole picture and may arrange a biopsy or transfer quickly.Walang iisang pagsusuri na makapagsasabing walang malubhang pamamaga ng salaan. Maaaring negatibo ang antibody test, at maaaring hindi makita ng mikroskopyo ang mga sirang selula. Kung bumababa ang paggana ng bato mo, kikilos ang team batay sa buong larawan at maaaring mag-ayos agad ng biopsy o paglipat.Walay usa ka pagsusi nga makaingon nga walay grabeng panghubag sa salaan. Mahimong negatibo ang antibody test, ug mahimong dili makita sa mikroskopyo ang gubang mga selula. Kung nagkunhod ang paglihok sa imong kidney, molihok ang team base sa tibuok hulagway ug mahimong mohikay dayon og biopsy o pagbalhin.Ala yang metung a pamanyuri a makapagsabing ala yang marine a pamamaga ning salaan. Malyari yang negatibu ing antibody test, at malyaring e la akit ning mikroskopyu deng siran selula. Nung bababa ing pamagobra ning bató mu, kikilus ing team batay king sablang larawan at malyari yang mag-ayus agad ning biopsy o pamaglipat.

Labeled schematic of what the lab sees under the microscope: on the left, normal round red blood cells typical of bleeding from the bladder; in the center, misshapen red blood cells with small knob-like blebs called acanthocytes; on the right, a cylinder-shaped red blood cell cast. Each is captioned in plain words.

Under the microscope: round red cells can come from anywhere in the urinary tract; misshapen cells (acanthocytes) and red cell casts point to the kidney filters.Sa mikroskopyo: maaaring manggaling kahit saan sa daanan ng ihi ang bilog na red cell; ang mga sirang selula (acanthocyte) at red cell cast ay tumuturo sa mga salaan ng bato.Sa mikroskopyo: mahimong gikan bisan asa sa agianan sa ihi ang lingin nga red cell; ang gubang mga selula (acanthocyte) ug red cell cast nagtudlo sa mga salaan sa kidney.King mikroskopyu: malyari lang manibat nung nukarin man king dalan ning ume deng bilug a red cell; deng siran selula (acanthocyte) ampo red cell cast tuturu la kareng salaan ning bató.

RBC
Red blood cell

Treatment follows the causeSumusunod sa sanhi ang gamutanMosunod sa hinungdan ang pagtambalTutulad king sanhi ing panamuyut

Two kinds of care happen together. Supportive care protects you while the kidneys heal: controlling blood pressure, limiting salt, using water pills (diuretics) if fluid builds up, managing potassium, and, when needed, temporary dialysis. Cause-directed care targets what is driving the inflammation.Dalawang uri ng pangangalaga ang sabay na nangyayari. Supportive care na nagpoprotekta sa iyo habang gumagaling ang bato: pagkontrol ng presyon, pagbawas ng asin, paggamit ng pampaihi (diuretic) kung naiipon ang tubig, pag-aayos ng potassium, at, kung kailangan, pansamantalang dialysis. Gamutang nakatuon sa sanhi na tumatarget sa nagpapamaga.Duha ka klase sa pag-atiman ang dungan nga mahitabo. Supportive care nga manalipod kanimo samtang naayo ang kidney: pagkontrol sa presyon, pagkunhod sa asin, paggamit og pang-ihi (diuretic) kung natigom ang tubig, pagdumala sa potassium, ug, kung kinahanglan, temporaryong dialysis. Pagtambal nga nakatutok sa hinungdan nga motarget sa nagpahubag.Adwang klasi ning pamangalaga ing sabay a malyari. Supportive care a magprotekta keka kabang manyakit ing bató: pamagkontrol king presyun, pamabawas king asin, pamangamit pamaume (diuretic) nung metipun ya ing danum, pamag-ayus king potassium, at, nung kailangan, pansamantalang dialysis. Panamuyut a tutuki king sanhi a tatarget king pamapamaga.

How certain is the evidence? For vasculitis, anti-GBM disease, and lupus, prompt immune treatment is among the best-established ways to protect the kidneys; delays cost kidney function. For IgA nephropathy, several newer medicines clearly slow the loss of kidney function in large trials over about two years, but how they compare with each other and their very long-term effects are still being studied. For strep-related disease in children, recovery is the rule.Gaano katiyak ang ebidensya? Para sa vasculitis, anti-GBM disease, at lupus, ang mabilis na immune treatment ay kabilang sa pinakanapatunayang paraan para maprotektahan ang bato; nawawalan ng paggana ng bato kapag naantala. Para sa IgA nephropathy, malinaw na pinababagal ng ilang mas bagong gamot ang pagkawala ng paggana ng bato sa malalaking pag-aaral sa loob ng mga dalawang taon, pero pinag-aaralan pa kung paano sila naghahambing sa isa't isa at ang napakatagal na epekto nila. Para sa sakit na kaugnay ng strep sa mga bata, karaniwang gumagaling.Unsa ka sigurado ang ebidensya? Para sa vasculitis, anti-GBM disease, ug lupus, ang dali nga immune treatment usa sa labing napamatud-an nga paagi aron mapanalipdan ang kidney; mawad-an og paglihok sa kidney kung maulahi. Para sa IgA nephropathy, klaro nga gipahinay sa pipila ka mas bag-ong tambal ang pagkawala sa paglihok sa kidney sa dagkong pagtuon sulod sa mga duha ka tuig, apan gitun-an pa kung unsaon nila pagtandi sa usag usa ug ang ilang taas kaayong epekto. Para sa sakit nga may kalabutan sa strep sa mga bata, kasagaran mamaayo.Makananu kasigurado ing ebidensya? Para king vasculitis, anti-GBM disease, ampo lupus, ing mabilis a immune treatment kayabe kareng pekapatunayan a paralan ban aprotektan ing bató; mawawalan pamagobra ing bató nung maantala. Para king IgA nephropathy, malino a pakupadan da reng aliwang mas bayung gamut ing pamanawala ning pamagobra ning bató kareng maragul a pag-aral king lalam ning adwang banwa, dapot pag-aralan pa nung makananu la miyabe-abe at ing pekamaragal dang epektu. Para king sakit a misasaup king strep kareng anak, karaniwan manyakit la.

While you wait for answersHabang naghihintay ng sagotSamtang naghulat og tubagKabang maghintay king sagut

Five simple illustrated action tiles on a white background: a folder of lab papers and a pill list labeled bring your records; a crossed-out pain-reliever blister pack; a salt shaker with a downward arrow; a home blood pressure monitor; and a calendar page with a check mark for follow-up.

While you wait: bring your records, skip anti-inflammatory pain relievers, go easy on salt, check your blood pressure, and keep every follow-up.Habang naghihintay: dalhin ang iyong mga record, iwasan ang anti-inflammatory na pain reliever, bawasan ang asin, sukatin ang presyon, at huwag palampasin ang follow-up.Samtang naghulat: dad-a ang imong mga rekord, likayi ang anti-inflammatory nga pain reliever, kunhori ang asin, sukda ang presyon, ug ayaw laktawi ang follow-up.Kabang maghintay: darun mu deng rekord mu, iwasan ing anti-inflammatory a pain reliever, bawasan ing asin, sukatan ing presyun, at e mu lalaktawan ing follow-up.

⚠️

Pregnant or recently gave birth?Buntis o kapapanganak lang?Mabdos o bag-o lang nanganak?Mabdus o bayu kang menganak?

High blood pressure with protein or blood in the urine during or after pregnancy needs same-day review. Preeclampsia and other pregnancy-related conditions can look like kidney filter inflammation and need both your obstetrician and a nephrologist.Kailangang suriin sa parehong araw ang mataas na presyon na may protina o dugo sa ihi habang o pagkatapos magbuntis. Maaaring magmukhang pamamaga ng salaan ang preeclampsia at iba pang kondisyong kaugnay ng pagbubuntis at kailangan ng iyong obstetrician at nephrologist.Kinahanglang susihon sa samang adlaw ang taas nga presyon nga adunay protina o dugo sa ihi samtang o human sa pagmabdos. Mahimong murag panghubag sa salaan ang preeclampsia ug ubang kondisyon nga may kalabutan sa pagmabdos ug kinahanglan ang imong obstetrician ug nephrologist.Kailangan yang suryan king pareung aldo ing matas a presyun a atin protina o daya king ume kabang o kaybat ning pamagbuntis. Malyari yang anti pamamaga ning salaan ing preeclampsia ampo aliwang kundisyun a misasaup king pamagbuntis at kailangan de ing obstetrician mu ampo nephrologist.

Common questionsMga karaniwang tanongKasagarang pangutanaKaraniwang kutang

Is nephritic syndrome the same as kidney failure?Pareho ba ang nephritic syndrome at kidney failure?Pareho ba ang nephritic syndrome ug kidney failure?Pareu ya ing nephritic syndrome ampo kidney failure?
No. It describes inflamed filters. Kidney function may be normal, mildly reduced, or falling fast. Many people recover well, especially with early treatment.Hindi. Inilalarawan nito ang namamagang salaan. Maaaring normal, bahagyang bumaba, o mabilis na bumababa ang paggana ng bato. Maraming gumagaling nang maayos, lalo na kung maagang nagamot.Dili. Gihulagway niini ang nanghubag nga salaan. Mahimong normal, gamay nga mikunhod, o paspas nga nagkunhod ang paglihok sa kidney. Daghan ang maayo nga mamaayo, labi na kung sayo natambalan.Ali. Ilarawan na ing mamagang salaan. Malyari yang normal, mekaunting mibaba, o mabilis a bababa ing pamagobra ning bató. Dakal ing manyakit mayap, lalu na nung asne magamut.
Will I need dialysis?Kailangan ko ba ng dialysis?Kinahanglan ba nako og dialysis?Kailangan ku wari ing dialysis?
Most people do not. Some need dialysis for a short time while the kidneys recover; a few need it longer. Your team will explain your situation based on your blood tests and biopsy.Karamihan ay hindi. May ilang nangangailangan ng dialysis sa maikling panahon habang gumagaling ang bato; kaunti ang nangangailangan nang mas matagal. Ipapaliwanag ng team ang sitwasyon mo batay sa pagsusuri ng dugo at biopsy.Kadaghanan dili. Ang uban magkinahanglan og dialysis sa mubo nga panahon samtang naayo ang kidney; pipila ang magkinahanglan og mas dugay. Ipasabot sa team ang imong kahimtang base sa pagsusi sa dugo ug biopsy.Dakal ing ali. Atin kareng mangailangan dialysis king malating panaun kabang manyakit ing bató; mekaunti ing mangailangan mas mabayu. Ipaliwanag ning team ing kalagayan mu batay king pamanyuri king daya ampo biopsy.
Is a kidney biopsy dangerous?Mapanganib ba ang kidney biopsy?Delikado ba ang kidney biopsy?Mapanganib ya ing kidney biopsy?
It is a common, generally safe procedure done with ultrasound guidance. The main risk is bleeding, usually minor; serious bleeding is uncommon. Your team checks blood pressure and clotting first and watches you for several hours afterward.Karaniwan at karaniwang ligtas na pamamaraan ito na ginagawa gamit ang ultrasound. Ang pangunahing panganib ay pagdurugo, karaniwang bahagya; bihira ang malubhang pagdurugo. Sinusuri muna ng team ang presyon at pamumuo ng dugo at binabantayan ka nang ilang oras pagkatapos.Kasagaran ug kasagarang luwas nga pamaagi kini nga gihimo gamit ang ultrasound. Ang pangunang peligro mao ang pagdugo, kasagaran gamay; talagsa ang grabeng pagdugo. Susihon una sa team ang presyon ug pagbaga sa dugo ug bantayan ka sulod sa pipila ka oras human.Karaniwan at karaniwang ligtas a pamamaralan ya iti a gagawan gamit ing ultrasound. Ing pangunang panganib iyang pamagdaya, karaniwan mekaunti; bihira ing marine a pamagdaya. Surian mune ning team ing presyun ampo pamamu ning daya at bantayan da ka king lalam ning aliwang oras kaybat.
Can it come back?Maaari ba itong bumalik?Mahimo ba kining mobalik?Malyari yang mibalik?
It depends on the cause. Strep-related disease rarely returns. IgA nephropathy, lupus, and vasculitis can flare again, which is why long-term follow-up with urine and blood tests matters.Nakadepende sa sanhi. Bihirang bumalik ang sakit na kaugnay ng strep. Maaaring sumumpong muli ang IgA nephropathy, lupus, at vasculitis, kaya mahalaga ang pangmatagalang follow-up na may pagsusuri ng ihi at dugo.Nagdepende sa hinungdan. Talagsa mobalik ang sakit nga may kalabutan sa strep. Mahimong mosumpong pag-usab ang IgA nephropathy, lupus, ug vasculitis, mao nga importante ang dugay nga follow-up nga adunay pagsusi sa ihi ug dugo.Makadepende king sanhi. Bihira yang mibalik ing sakit a misasaup king strep. Malyari lang sumumpung pasibayu ing IgA nephropathy, lupus, ampo vasculitis, kaya mayalaga ing mabayung follow-up a atin pamanyuri king ume ampo daya.
Should I take herbal remedies to “clean” my kidneys?Dapat ba akong uminom ng herbal para “linisin” ang bato?Angay ba ko moinom og herbal aron “limpyohan” ang kidney?Dapat ku wari uminum herbal ban “linisan” ing bató?
No herbal product treats glomerulonephritis, and some contain substances that injure the kidney or interact with treatment. Show any product to your team before taking it.Walang herbal na produktong gumagamot sa glomerulonephritis, at may ilang naglalaman ng sangkap na nakapipinsala sa bato o sumasalungat sa gamutan. Ipakita sa team ang anumang produkto bago inumin.Walay herbal nga produkto nga motambal sa glomerulonephritis, ug ang uban adunay sangkap nga makadaot sa kidney o mosupak sa pagtambal. Ipakita sa team ang bisan unsang produkto sa dili pa imnon.Ala yang herbal a produktu a manamuyut king glomerulonephritis, at atin kareng atin sangkap a makapasakit king bató o sasalungat king panamuyut. Ipakit mu king team ing anumang produktu bayu mu inumen.

A pattern, a tempo, and a lesion: keep the three apart

Nephritic syndrome is a clinical pattern: glomerular hematuria, usually with some proteinuria, often with hypertension, edema, and a falling glomerular filtration rate (GFR). The full cluster need not be present. Rapidly progressive glomerulonephritis (RPGN) is a tempo — loss of kidney function over days to weeks. Crescents are a biopsy lesion. None of the three names the cause, and a patient can carry nephritic and nephrotic features at once. The clinician’s task in the first hours is to recognize the pattern, judge its speed, and start the parallel work-up that leads to a cause.

From injury to bedside signs

The glomerular capillary wall is a three-layer filter — fenestrated endothelium, glomerular basement membrane (GBM), and podocyte slit diaphragms — that normally excludes cells and retains albumin. Nephritic injury is endocapillary and inflammatory. Immune complexes deposited in situ or from the circulation (immunoglobulin A [IgA], lupus, infection-related), antibodies directed at the GBM itself, or neutrophils primed by antineutrophil cytoplasmic antibodies (ANCA) activate complement and recruit leukocytes. Proteases and oxidants break the capillary wall. Red cells forced through those breaks are deformed by mechanical and osmotic stress along the tubule, emerging as dysmorphic cells and acanthocytes, and they are trapped in Tamm–Horsfall protein to form red blood cell casts.

The same lesion explains the physiology at the bedside. Endocapillary proliferation and capillary occlusion reduce the filtration surface area and the ultrafiltration coefficient, so GFR falls even before scarring. Distal nephron sodium reabsorption rises despite expanded extracellular volume — a primary sodium-retention state with suppressed renin. Volume expansion, not renin, drives the hypertension and edema; this is why loop diuretics and sodium restriction work early, and why a renin–angiotensin blocker alone is often insufficient in the acute phase. When rupture of Bowman’s capsule lets fibrin and macrophages into Bowman’s space, parietal epithelial proliferation forms a cellular crescent; untreated, crescents organize into fibrous scars within weeks. That time course is the physiologic reason RPGN is an emergency: a cellular crescent is potentially reversible, a fibrous one is not.

Cross-organ links follow from the cause. The same autoantibody that targets the GBM also targets alveolar basement membrane (pulmonary–renal syndrome). ANCA vasculitis injures small vessels in the upper airway, lung, skin, and nerves. Endocarditis and chronic infections sustain immune-complex formation until the source is controlled. Volume overload strains the heart; uremia and hyperkalemia disturb rhythm and neurologic function.

Review-article style mechanism figure. Top left: a kidney with one nephron highlighted. Dashed magnification panel: a glomerular capillary loop showing immune-complex deposits, complement activation, neutrophils, a break in the basement membrane, red cells squeezing into Bowman's space, and a cellular crescent forming. Bottom flow: injury, then consequences (hematuria, red cell casts, sodium retention, hypertension, falling GFR), then intervention targets (source control, immunosuppression, plasma exchange, supportive care).

Mechanism: immune injury breaks the glomerular capillary wall, red cells leak and are deformed, sodium is retained, GFR falls, and Bowman’s capsule rupture leads to crescents that scar within weeks unless the cause is treated.

GBM
Glomerular basement membrane
ANCA
Antineutrophil cytoplasmic antibodies
GFR
Glomerular filtration rate
RBC
Red blood cell

First hours and first visit: escalate and investigate in parallel

⛔

Do not wait for a score or a serology result to escalate

Suspected diffuse alveolar hemorrhage (which can occur without hemoptysis), pulmonary edema with respiratory compromise, hypertensive emergency, severe hyperkalemia or acidosis, uremic complications, or near-anuria with deterioration warrants emergency care and immediate nephrology involvement. A rapidly rising creatinine with glomerular sediment warrants same-day nephrology assessment; arrange transfer if biopsy, dialysis, plasma exchange, or specialist treatment is unavailable.1,3

Five parallel steps
1
Stabilize and judge tempo. Oxygenation, blood pressure and end-organ symptoms, urine output, volume status, potassium, acid–base status, and the creatinine trajectory against a documented, timestamped baseline. Stage acute kidney injury (AKI) by measured creatinine and urine output; conventional estimated GFR (eGFR) equations assume steady state and mislead during AKI.6
2
Confirm the pattern. Fresh clean-catch urinalysis with microscopy by an experienced reader; electrolytes and bicarbonate; complete blood count; albumin; quantitative proteinuria by spot urine protein-to-creatinine ratio (UPCR), with a timed collection when precise quantification would change management. UPCR measures total protein; the urine albumin-to-creatinine ratio (UACR) measures albumin; neither is a measured g/day. Dipstick heme without red cells suggests pigment or lysis. A nephrotic-range result does not exclude nephritis.
3
Send serology by tempo and phenotype. C3 and C4 in all. For RPGN or lung–kidney features, send anti-GBM antibody and antigen-specific ANCA (myeloperoxidase [MPO] and proteinase 3 [PR3]) urgently and together. Add antinuclear antibody (ANA) and anti-double-stranded DNA (anti-dsDNA) for suspected lupus; blood cultures and echocardiography when endocarditis is plausible; streptococcal serology where relevant; hepatitis B and C, human immunodeficiency virus (HIV), cryoglobulins (warm transport), and monoclonal protein studies when indicated. Draw cultures before antibiotics and serology before plasma exchange when this does not delay care.
4
Plan the biopsy. Arrange it when it will clarify diagnosis, activity, or chronicity, or alter treatment; request light microscopy, immunofluorescence, and electron microscopy. In suspected anti-GBM disease, start specialist-directed treatment while confirmation is pending. In a compatible, rapidly deteriorating presentation with positive MPO- or PR3-ANCA, Kidney Disease: Improving Global Outcomes (KDIGO) advises against delaying immunosuppression solely to obtain a biopsy, while infection is excluded in parallel.1,3,8
5
Close the loop. Name who reviews each pending test, when creatinine and potassium will be repeated, and which symptoms trigger earlier review. Manage sodium, volume, and blood pressure; revisit renin–angiotensin system (RAS) blockade and sodium–glucose cotransporter 2 (SGLT2) inhibitors once acute instability settles. In pregnancy or postpartum, consider preeclampsia and thrombotic microangiopathy (TMA) alongside glomerulonephritis (GN), with joint obstetric and nephrology care.
Clinical algorithm flowchart titled First hours in suspected nephritic syndrome. Top box: glomerular hematuria with or without proteinuria, hypertension, edema, or rising creatinine. A red emergency branch lists hypoxemia or suspected alveolar hemorrhage, pulmonary edema, hypertensive emergency, severe hyperkalemia or acidosis, near-anuria, leading to emergency care and immediate nephrology. The main column shows parallel steps: confirm pattern with urine microscopy and quantified proteinuria; serology C3, C4 and, for rapid or lung-kidney presentations, anti-GBM plus MPO and PR3 ANCA together; infection screen; ultrasound; biopsy planning; and a closing box for follow-up ownership.

First-hours pathway: emergency features trigger immediate escalation; otherwise confirm the pattern, send serology matched to tempo, exclude infection, and plan the biopsy — all in parallel. A text version is in the steps above.

AKI
Acute kidney injury
ANCA
Antineutrophil cytoplasmic antibodies
GBM
Glomerular basement membrane
MPO
Myeloperoxidase
PR3
Proteinase 3
UPCR
Urine protein-to-creatinine ratio

What each test can and cannot tell you

TestUseful signalPitfalls
Urine sedimentAcanthocytes and/or red blood cell casts support a glomerular source. In a biopsy-linked referral cohort, either finding had 75% sensitivity and 86% specificity for GN and was present in 47 of 51 crescentic or necrotizing cases.7Single-center, expert microscopy, high pretest probability. Absence cannot rule out GN; never use it as a rule-out test.
ProteinuriaUPCR (total protein) for trend; timed collection for decisions needing precision. For the same analyte, mg/g = mg/mmol × 8.84.Spot ratios are not measured g/day and vary with creatinine excretion; never mix UPCR, UACR, and timed values in one series.
C3 / C4Low C3 with normal C4 suggests infection-related GN or C3 glomerulopathy; low C3 and C4 suggests lupus or cryoglobulinemia (often very low C4).Normal complement does not exclude IgA nephropathy, ANCA disease, or anti-GBM disease. Endocarditis can lower complement and induce ANCA.
MPO/PR3-ANCA, anti-GBMSend together in RPGN; double positivity is common enough that one result never excuses the other, and it changes relapse risk and maintenance.8Positive ANCA in endocarditis or drug exposure; seronegative anti-GBM disease exists when suspicion is strong and the biopsy shows linear immunoglobulin G (IgG).
Creatinine and eGFRSerial measured creatinine stages AKI against a credible baseline.eGFR equations assume steady state; an eGFR decline is never an urgency gate during AKI.
Clinician reference map titled Narrowing the cause of nephritic syndrome. Columns for serum complement (low C3 normal C4; low C3 and low C4; normal), each listing candidate diseases with key clues: infection-related GN and C3 glomerulopathy; lupus nephritis and cryoglobulinemic GN; IgA nephropathy, IgA vasculitis, ANCA-associated vasculitis, and anti-GBM disease. Footer notes that complement patterns are clues, not diagnoses, and that biopsy immunofluorescence (granular, linear, pauci-immune, C3-dominant) confirms the category.

Complement and immunofluorescence narrow the category, but they are clues rather than verdicts; endocarditis, overlap syndromes, and normal-complement disease all break simple rules.

C3/C4
Complement components 3 and 4
ANCA
Antineutrophil cytoplasmic antibodies
GBM
Glomerular basement membrane
GN
Glomerulonephritis
IgA
Immunoglobulin A

Cause-specific clues and what changes management

PatternClues and discriminatorsWhat changes management
IgA nephropathy (IgAN) / IgA vasculitis (IgAV)Gross hematuria during or within days of a respiratory infection; C3/C4 usually normal. Purpura, abdominal pain, and arthralgia suggest IgAV. Biopsy: IgA-dominant mesangial staining; exclude secondary IgA and IgA-dominant infection-related GN.KDIGO 2025: consider biopsy in adults with proteinuria ≥0.5 g/day (or equivalent) if feasible and safe. In confirmed IgAN, target proteinuria <0.5 g/day, ideally <0.3 g/day, with stable function. Pair supportive care with specialist discussion of disease-directed options. IgAV follows a separate pathway.2
ANCA-associated vasculitis (AAV)Upper airway, lung, skin, or nerve involvement, or kidney-limited disease. Complement usually normal. Pauci-immune necrotizing crescentic GN; a minority are ANCA-negative.Severe renal AAV: rituximab or cyclophosphamide with a reduced-dose glucocorticoid strategy. KDIGO 2024 suggests considering plasma exchange for creatinine >3.4 mg/dL (>300 µmol/L), dialysis, rapidly rising creatinine, or diffuse alveolar hemorrhage with hypoxemia, and adding it in ANCA/anti-GBM overlap.3
Anti-GBM diseaseAbrupt renal decline with or without lung hemorrhage; linear glomerular IgG. Test for ANCA co-positivity.Immediate plasma exchange, glucocorticoids, and cyclophosphamide. KDIGO’s exception applies only to selected patients already on dialysis whose adequate biopsy shows 100% crescents or >50% global sclerosis and who have no pulmonary hemorrhage; never automate withholding. Double-positive disease carries AAV-type relapse risk.1,8
Lupus nephritis (LN)Systemic lupus erythematosus (SLE) features; often low C3/C4 and positive anti-dsDNA. “Full-house” immunofluorescence supports LN in context.KDIGO uses ≥500 mg/day as a point to consider biopsy; the American College of Rheumatology (ACR) conditionally recommends biopsy for proteinuria >0.5 g/g or unexplained impaired function. Active class III/IV ± V: glucocorticoids plus mycophenolic acid analogs or low-dose intravenous cyclophosphamide, or selected combinations with belimumab or a calcineurin inhibitor; ACR conditionally prefers triple therapy.4,5
Infection-related GN (IRGN)Post-streptococcal disease follows pharyngitis by about 10 days or skin infection by up to 3 weeks. Adults often have ongoing staphylococcal infection, diabetes, or endocarditis. Low C3 with preserved C4; subepithelial humps or IgA-dominant deposits.Treat the infection and its source; manage volume, blood pressure, and complications; eradicate residual group A streptococcus in post-streptococcal GN (PSGN). Avoid reflex immunosuppression. In typical pediatric PSGN, recheck C3 and kidney function around 8 weeks; persistent low C3 or worsening prompts reassessment.1,32,33
C3 glomerulopathy (C3G) / immune-complex membranoproliferative GN (IC-MPGN)MPGN is a pattern of injury. C3-dominant immunofluorescence supports C3G after excluding infection and monoclonal gammopathy; electron microscopy separates dense deposit disease from C3 GN. Serum C3 may be normal.Evaluate infection, autoimmunity, monoclonal protein, and complement dysregulation before calling the process primary. Complement inhibitors reduce proteinuria in selected populations (US indications differ: iptacopan for adult C3G; pegcetacoplan for C3G or primary IC-MPGN from age 12). Vaccinate against encapsulated bacteria before use.22,23
Other causes and mimicsCryoglobulinemic GN (very low C4, purpura, neuropathy, hepatitis C); TMA (hemolysis, thrombocytopenia, severe hypertension, pregnancy); collagen IV (COL4A3–5) disease (familial hematuria, hearing loss); stones, infection, malignancy, contamination, pigmenturia, interstitial nephritis.Run parallel pathways: a glomerular source does not cancel an indicated urologic evaluation in an older adult. TMA is time-critical. Children need age-appropriate blood pressure and urine interpretation and pediatric nephrology.
🔬

IgAN exception box: rapidly progressive IgAN is a disease-specific definition

KDIGO defines rapidly progressive IgAN as a ≥50% fall in eGFR over ≤3 months after other causes of RPGN and reversible factors are excluded. It is a classification for IgAN, never an escalation threshold for undiagnosed nephritis. Crescents without a matching functional decline do not establish it. After biopsy and exclusion of competing causes, KDIGO advises offering cyclophosphamide and glucocorticoids under specialist care.2

Reading the biopsy report

Ask for adequacy (number of glomeruli), the proportion of normal glomeruli, necrosis, the crescent mix (cellular, fibrocellular, fibrous), and interstitial fibrosis and tubular atrophy (IFTA). Activity lesions (necrosis, cellular crescents, endocapillary proliferation) predict response; chronicity lesions (fibrous crescents, global sclerosis, IFTA) predict what cannot be recovered. Crescent burden alone does not select a regimen; the diagnosis does.

Clean teaching panel titled What the biopsy shows. Three glomeruli drawn side by side: a normal glomerulus; an active lesion with fibrinoid necrosis and a cellular crescent labeled potentially reversible; and a chronic lesion with a fibrous crescent and global sclerosis labeled scarred. Below, small immunofluorescence insets show granular, linear, pauci-immune, and C3-dominant staining patterns with their associated disease categories.

Active lesions (necrosis, cellular crescents) are the treatable target; fibrous crescents and global sclerosis are scar. Immunofluorescence pattern — granular, linear, pauci-immune, or C3-dominant — points to the disease category.

IF
Immunofluorescence
IFTA
Interstitial fibrosis and tubular atrophy
IgG
Immunoglobulin G
C3
Complement component 3

Evidence cards: guidelines first, trials second

Guideline statements and trial results are shown separately. Each card states population, comparator, endpoint, horizon, effect with 95% confidence interval (CI), and an applicability limit. Results come from different populations and endpoints; do not rank drugs across trials or assume that benefits add. Labels: Kidney function eGFR slope or composite kidney outcome; Surrogate proteinuria or response definition; Diagnostic / prognostic.

IgA nephropathy

TrialPopulation and comparatorResultApplicability
APPLAUSE-IgAN (iptacopan), 202612477 adults, eGFR ≥30, UPCR ≥1 g/g despite supportive care; vs placebo, 24 monthsSlope −3.10 vs −6.12 mL/min/1.73 m²/yr; difference +3.02 (95% CI 2.02 to 4.01). Composite kidney endpoint 21.4% vs 33.5% (hazard ratio [HR] 0.57, 0.40 to 0.81). Serious infections 6.7% vs 2.1%.Composite includes ≥30% eGFR decline, not dialysis alone. Complement-inhibitor infection precautions apply.
VISIONARY (sibeprenlimab), 202613510 adults with IgAN at risk; vs placebo, 24 monthsSlope +0.3 vs −4.2; difference +4.5 (3.6 to 5.4). Composite kidney endpoint 0.4% vs 11.2%.Within-trial comparison in a selected population; no head-to-head data.
ORIGIN 3 (atacicept), 202614428 treated adults with biopsy-proven IgAN; vs placebo, 104 weeksSlope −0.60 vs −5.60; difference +5.00 (3.55 to 6.45). Progression composite 5.1% vs 17.8% (HR 0.24, 0.12 to 0.48).US approval (July 7, 2026) preceded these results; check the current label.31
RAINIER (povetacicept), interim, 202615First 199 randomized of 557; vs placebo, 36 weeksSurrogate UPCR −52.0% vs −4.3% (adjusted difference −49.8 percentage points, −58.6 to −39.2).Interim proteinuria only; long-term kidney benefit not yet shown.
ALIGN (atrasentan), 202616340 adults (main stratum) on RAS inhibition; vs placebo, 136 weekseGFR week-136 change difference +2.4 (−0.1 to 4.8; P = 0.057). Total slope difference +1.4 mL/min/1.73 m²/yr (0.5 to 2.3).Key secondary endpoint CI crosses zero; report slope separately.
NefIgArd (targeted-release budesonide), 202317364 adults on optimized RAS blockade; 9 months of therapy, 2-year follow-upeGFR time-weighted average difference +5.05 mL/min/1.73 m² (3.24 to 7.38).Formulation-specific; a time-weighted average is not an annual slope.
PROTECT (sparsentan vs irbesartan), 202318404 adults with persistent proteinuria; active comparator, 110 weeksSlope chronic slope difference +1.1 (0.1 to 2.1); total slope difference +1.0 (−0.03 to 1.94).Sparsentan replaces, not adds to, an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).

How to read the IgAN cards. eGFR slope is an accepted surrogate for long-term kidney failure in IgAN, and the composite endpoints in APPLAUSE and ORIGIN 3 move in the same direction, so these trials demonstrate slower loss of kidney function over about two years. They do not yet show effects on dialysis or death, and they cannot be ranked against each other. KDIGO’s 2026 commentary and the Kidney Disease Outcomes Quality Initiative (KDOQI) US commentary add context to, but do not replace, the 2025 guideline.19,20 Supportive care — tolerated RAS blockade and SGLT2 inhibition in eligible patients — remains the foundation.

ANCA vasculitis, lupus nephritis, complement disease, infection-related GN

EvidencePopulation and comparatorResultApplicability
PEXIVAS, 20209704 with severe AAV (eGFR <50 or diffuse pulmonary hemorrhage); plasma exchange vs none (factorial with glucocorticoid dose)Outcome Death or kidney failure 28.4% vs 31.0% (HR 0.86, 0.65 to 1.13). Reduced-dose glucocorticoids noninferior, with fewer serious infections at 1 year (incidence rate ratio 0.69, 0.52 to 0.93).Does not support routine exchange in all severe AAV; separate from KDIGO high-risk considerations and anti-GBM overlap.
Plasma exchange meta-analysis, 202210Randomized trials in AAV (999 participants for kidney failure)Outcome 12-month kidney failure risk ratio (RR) 0.62 (0.39 to 0.98); serious infections RR 1.27 (1.08 to 1.49).Benefit and harm move in opposite directions; absolute effect depends on baseline risk. Adds context to PEXIVAS rather than overturning it.
REGENCY (obinutuzumab), 202521271 adults with active LN on mycophenolate and glucocorticoids; vs placebo, 76 weeksResponse Complete renal response 46.4% vs 33.1% (difference +13.4 points, 2.0 to 24.8).Protocol-defined response, not histologic remission; more serious adverse events, mainly infections. Post-guideline evidence.
VALIANT (pegcetacoplan), 202522124 adolescents and adults with C3G or primary IC-MPGN; vs placebo, 26 weeksSurrogate UPCR 68.1% relative reduction vs placebo (57.3 to 76.2).Histologic activity did not meet the testing hierarchy; short-term proteinuria only.
APPEAR-C3G (iptacopan), 20252374 adults with native-kidney C3G and low C3; vs placebo, 6 monthsSurrogate UPCR 35.1% relative reduction vs placebo (13.8 to 51.1).Different population and design from VALIANT; do not rank by effect size.
Corticosteroids in adult IRGN, 20222452 adults with biopsy-proven IRGN; steroids plus supportive care vs supportive care, 6 monthsOutcome Complete recovery 65.4% vs 53.8% (odds ratio 1.6, 0.5 to 4.9). Adverse events 46.2% vs 7.7%.Small single-center trial; does not support routine steroids.
Urine microscopy, 20257276 biopsied referral patients; expert sediment within 2 weeks of biopsyDiagnostic Acanthocytes and/or casts: sensitivity 75%, specificity 86% for GN.Not a rule-out test; do not feed into a probability calculator.
ANCA Kidney Risk Score (AKRiS), 2024111,439 with biopsy-proven renal AAV; development and validation cohortsPrognostic Four strata; 3-year kidney survival 96%, 79%, 54%, 19% in the development cohort (C statistic 0.831).Group-level prognosis; does not select dialysis, plasma exchange, or immunosuppression.
⚠️

Safety update: avacopan

The journal retracted the ADVOCATE trial on June 29, 2026, after concerns about the integrity of primary-endpoint adjudication. Do not use its efficacy estimates or copy the avacopan option from the 2024 AAV guideline into a pathway; read KDIGO’s 2026 response alongside it.27,28 The US Food and Drug Administration (FDA) identified serious liver injury and proposed withdrawal; the European Commission issued a binding revocation on August 4, 2026 — separate regulatory actions.29,30 Patients already taking it should discuss their treatment with their specialist and never stop or switch on their own. Verify Philippine status before any local statement.

Making the pathway work locally

Six cases, six traps

1. Cola urine during a sore throat Synpharyngitic hematuria

A 26-year-old has visible hematuria on day two of pharyngitis; C3/C4 are normal, creatinine is stable, and UPCR is 0.9 g/g on repeat. Quantify again, assess for IgAN, and discuss biopsy in context. Trap: timing and normal complement are clues, not a diagnosis.

2. Child with edema two weeks after pharyngitis Typical PSGN

A 7-year-old has puffy eyelids, blood pressure above the 95th percentile, and low C3 with normal C4. Treat blood pressure and volume now and eradicate residual strep. If typical and stable under pediatric care, record a C3 and kidney-function recheck around 8 weeks. Trap: persistent low C3 or deterioration changes the pathway.

3. Creatinine 1.0 → 2.4 mg/dL in four days with RBC casts and hypoxemia Lung–kidney emergency

No hemoptysis. Activate the emergency pathway; send anti-GBM and MPO/PR3-ANCA together; evaluate infection; organize urgent transfer and biopsy. Trap: absence of hemoptysis does not exclude alveolar hemorrhage, and no calculator is needed to act.

4. Fever, murmur, hematuria, and positive PR3-ANCA Endocarditis mimic

Prioritize blood cultures and echocardiography with parallel nephrology assessment. Trap: ANCA positivity alone must not trigger immunosuppression; endocarditis can produce ANCA and low complement.

5. SLE with UPCR 0.8 g/g, rising creatinine, low C3/C4 Suspected active LN

Joint nephrology–rheumatology evaluation and prompt biopsy discussion. Distinguish active LN from chronic scarring, infection, and TMA. Trap: a response tracker is for follow-up after a classified, treated LN — not for diagnosis.

6. MPGN pattern and persistent low C3 after infection treatment C3G or ongoing driver?

Review immunofluorescence and electron microscopy; look for persistent infection, monoclonal protein, and complement dysregulation. Trap: low C3 alone does not establish C3G.

Tools that support — never replace — the decision

The new Nephritic Syndrome Toolkit runs entirely in the browser and stores nothing. Its trajectory tool shows emergency guidance even when every field is blank, and none of its outputs ever says “safe to wait.” Established tools on the site cover AKI staging, proteinuria conversion, and disease-specific prognosis after diagnosis.

🚫

Tools deliberately not built

No universal “nephritic probability” or urgency score, no complement-to-diagnosis classifier, no immunosuppression or plasma-exchange selector, no personalized benefit estimate from trial averages, and nothing that labels a patient safe because microscopy or serology is negative. The evidence does not support any of them, and each would invite delay.

Glossary & abbreviationsTalahulugan at mga daglatTalaan sa mga pulong ug daglatTalatinigan ampo reng daglat terms used in this guide

Abbreviations

AAV
ANCA-associated vasculitis
ACE
Angiotensin-converting enzyme
ACR
American College of Rheumatology
AKI
Acute kidney injury
AKRiS
ANCA Kidney Risk Score
ANA
Antinuclear antibody
ANCA
Antineutrophil cytoplasmic antibodies
ARB
Angiotensin receptor blocker
C3, C4
Complement components 3 and 4
C3G
C3 glomerulopathy
CI
Confidence interval
COL4A3–5
Collagen type IV alpha-3 to alpha-5 genes
anti-dsDNA
Anti-double-stranded DNA antibody
eGFR
Estimated glomerular filtration rate
EU
European Union
FDA
Food and Drug Administration
GBM
Glomerular basement membrane
GFR
Glomerular filtration rate
GN
Glomerulonephritis
HIV
Human immunodeficiency virus
HR
Hazard ratio
IC-MPGN
Immune-complex membranoproliferative glomerulonephritis
IF
Immunofluorescence
IFTA
Interstitial fibrosis and tubular atrophy
IgA
Immunoglobulin A
IgAN
IgA nephropathy
IgAV
IgA vasculitis
IgG
Immunoglobulin G
IRGN
Infection-related glomerulonephritis
KDIGO
Kidney Disease: Improving Global Outcomes
KDOQI
Kidney Disease Outcomes Quality Initiative
LN
Lupus nephritis
MPGN
Membranoproliferative glomerulonephritis
MPO
Myeloperoxidase
PR3
Proteinase 3
PSGN
Post-streptococcal glomerulonephritis
RAS
Renin–angiotensin system
RBC
Red blood cell
RPGN
Rapidly progressive glomerulonephritis
RR
Risk ratio
SGLT2
Sodium–glucose cotransporter 2
SLE
Systemic lupus erythematosus
TMA
Thrombotic microangiopathy
UACR
Urine albumin-to-creatinine ratio
UPCR
Urine protein-to-creatinine ratio
US
United States

Terms

Acanthocyte
A red blood cell with small knob-like blebs, deformed while passing through an inflamed filter; points to a glomerular source of bleeding.
Biopsy
Removal of a tiny piece of kidney with a thin needle so a pathologist can examine it under the microscope.
Complement
A group of blood proteins that helps the immune system attack germs; it can also injure the kidney when overactive. C3 and C4 levels are measured.
Crescent
A crescent-shaped collection of cells in Bowman’s space that forms after severe filter injury; cellular crescents may heal, fibrous ones are scar.
Creatinine
A muscle waste product in the blood; a rising level means the kidneys are filtering less.
Diuretic
A “water pill” that helps the kidneys remove extra salt and water.
Glomerulus (plural glomeruli)
A tiny ball of blood vessels that filters the blood; each kidney has about one million.
Immunofluorescence
A biopsy stain that shows which immune proteins (IgA, IgG, C3) are stuck in the filter and in what pattern.
Nephritic
Describing an inflamed, bleeding kidney filter, often with high blood pressure and swelling.
Nephrotic
Describing a filter that leaks large amounts of protein, causing marked swelling.
Plasma exchange
A procedure that removes the liquid part of the blood (with harmful antibodies) and replaces it with donor plasma or albumin.
Red blood cell cast
A tube-shaped plug of red blood cells formed in the kidney’s drainage tubules; a strong sign of filter bleeding.
eGFR slope
The yearly rate at which estimated kidney function changes; used in trials to measure how fast kidney disease progresses.
ReferencesMga SanggunianMga TinubdanReng Reperensya 33 sources
  1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. (2021). KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney International, 100(4S), S1–S276. https://doi.org/10.1016/j.kint.2021.05.021
  2. Rovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarchi, H., & Floege, J. (2025). KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney International, 108(4S), S1–S71. https://doi.org/10.1016/j.kint.2025.04.004
  3. Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. (2024). KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney International, 105(3S), S71–S116. https://doi.org/10.1016/j.kint.2023.10.008
  4. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. (2024). KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney International, 105(1S), S1–S69. https://doi.org/10.1016/j.kint.2023.09.002
  5. Sammaritano, L. R., Askanase, A., Bermas, B. L., Dall'Era, M., Duarte-García, A., Hiraki, L. T., Rovin, B. H., Son, M. B. F., Alvarado, A., Aranow, C., Barnado, A., Broder, A., Brunner, H. I., Chowdhary, V., Contreras, G., Felix, C., Ferucci, E. D., Gibson, K. L., Hersh, A. O., ... Mustafa, R. A. (2025). 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis & Rheumatology, 77(9), 1115–1135. https://doi.org/10.1002/art.43212
  6. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. (2012). KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements, 2(1), 1–138. https://doi.org/10.1038/kisup.2012.1
  7. Stark, A., Kanduri, S. R., Ramanand, A., Rosenbloom, S., Varghese, V., Chalmers, D. R., Velez, S. A., Gonzalez-Fuentes, C., Wickman, T. J., Mohamed, M., Shueib, A., Zarm, A., Lukitsch, I., Velasco-Gonzalez, C., Seltzer, J. R., & Velez, J. C. Q. (2025). Glomerular hematuria for the diagnosis of glomerulonephritis. Glomerular Diseases, 5(1), 206–218. https://doi.org/10.1159/000545051
  8. McAdoo, S. P., & Pusey, C. D. (2026). Anti-glomerular basement membrane disease—Treatment standard. Nephrology Dialysis Transplantation, 41(1), 42–54. https://doi.org/10.1093/ndt/gfaf190
  9. Walsh, M., Merkel, P. A., Peh, C. A., Szpirt, W. M., Puéchal, X., Fujimoto, S., Hawley, C. M., Khalidi, N., Floßmann, O., Wald, R., Girard, L. P., Levin, A., Gregorini, G., Harper, L., Clark, W. F., Pagnoux, C., Specks, U., Smyth, L., Tesar, V., ... Jayne, D. R. W. (2020). Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. The New England Journal of Medicine, 382(7), 622–631. https://doi.org/10.1056/NEJMoa1803537
  10. Walsh, M., Collister, D., Zeng, L., Merkel, P. A., Pusey, C. D., Guyatt, G., Au Peh, C., Szpirt, W., Ito-Hara, T., & Jayne, D. R. W. (2022). The effects of plasma exchange in patients with ANCA-associated vasculitis: An updated systematic review and meta-analysis. BMJ, 376, e064604. https://doi.org/10.1136/bmj-2021-064604
  11. Bate, S., McGovern, D., Costigliolo, F., Tan, P. G., Kratky, V., Scott, J., Chapman, G. B., Brown, N., Floyd, L., Brilland, B., Martín-Nares, E., Aydın, M. F., Ilyas, D., Butt, A., Nic An Riogh, E., Kollar, M., Lees, J. S., Yildiz, A., Hinojosa-Azaola, A., ... Brix, S. R. (2024). The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials. Journal of the American Society of Nephrology, 35(3), 335–346. https://doi.org/10.1681/ASN.0000000000000274
  12. Barratt, J., Eren, N., Kashihara, N., Maes, B., Rizk, D. V., Rovin, B., Trimarchi, H., Zhang, H., Wang, W., Kocyigit, I., Hao, C., Tesař, V., Turgutalp, K., Yang, L., Xing, G., Duro Garcia, V., Han, S. H., Lu, W., Pisani, A., ... Perkovic, V. (2026). Iptacopan in IgA nephropathy—Final 24-month data. The New England Journal of Medicine, 395(5), 465–477. https://doi.org/10.1056/NEJMoa2600743
  13. Rizk, D. V., Barratt, J., Suzuki, Y., Zhang, H., Wong, M. G., Liew, A., Lafayette, R., Tesař, V., Trimarchi, H., Carroll, K., Roberts, I. S. D., Jha, V., Quevedo, A., Han, S. H., Yahya, R., Cheung, C. K., Ramachandran, R., Walsh, M., Chacko, B., ... Perkovic, V. (2026). Sibeprenlimab in IgA nephropathy—Final phase 3 trial analysis. The New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMoa2609127
  14. Barratt, J., Brenner, R. M., Barbour, S. J., Campbell, K. N., Doan, T., Eren, N., Floege, J., Fordyce, M. W., Jha, V., Khawaja, Z., Kim, B. S., Liew, A., Maes, B., Pal, A., Pecoits-Filho, R., Phoon, R. K. S., Rizk, D. V., Suzuki, H., Tesař, V., ... Lafayette, R. (2026). Atacicept in IgA nephropathy—Phase 3 trial final efficacy analysis. The New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMoa2610103
  15. Barratt, J., Zhang, H., Han, S. H., Suzuki, Y., Tumlin, J., Chacko, B., Noronha, I. L., Madan, A., Duivenvoorden, R., Azzi, J. R., Nester, C., Dong, C., Ahluwalia, N., Li, J., Bozic, C., Egbuna, O., Wong, M. G., & Lafayette, R. (2026). Interim analysis of a phase 3 trial of povetacicept in IgA nephropathy. The New England Journal of Medicine, 395(18), 1830–1840. https://doi.org/10.1056/NEJMoa2608682
  16. Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., Choi, D. E., Lv, J., Trimarchi, H., Fu, P., Guenther, S., Yang, S., Liu, J., Rahalkar, S., Lodha, A., ... Barratt, J. (2026). Atrasentan in patients with IgA nephropathy (ALIGN): Final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 407(10546), 2387–2401. https://doi.org/10.1016/S0140-6736(26)00960-8
  17. Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Reich, H. N., Rovin, B. H., & Barratt, J. (2023). Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. The Lancet, 402(10405), 859–870. https://doi.org/10.1016/S0140-6736(23)01554-4
  18. Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D. W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., Kohan, D. E., Komers, R., Kooienga, L. A., Lafayette, R., Maes, B., Małecki, R., Mercer, A., Noronha, I. L., Oh, S. W., ... Perkovic, V. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. The Lancet, 402(10417), 2077–2090. https://doi.org/10.1016/S0140-6736(23)02302-4
  19. Rovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarchi, H., & Floege, J. (2026). Complement inhibitors and B cell-modifying agents for IgA nephropathy—A Kidney Disease: Improving Global Outcomes (KDIGO) commentary. Kidney International, 110(3), 502–507. https://doi.org/10.1016/j.kint.2026.03.003
  20. Ayoub, I., Coppock, G., Wadhwani, S., & Yau, T. (2026). KDOQI US commentary on the KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). American Journal of Kidney Diseases, 88(1), 18–35. https://doi.org/10.1053/j.ajkd.2026.02.639
  21. Furie, R. A., Rovin, B. H., Garg, J. P., Santiago, M. B., Aroca-Martínez, G., Zuta Santillán, A. E., Alvarez, D., Navarro Sandoval, C., Lila, A. M., Tumlin, J. A., Saxena, A., Irazoque Palazuelos, F., Raghu, H., Yoo, B., Hassan, I., Martins, E., Sehgal, H., Kirchner, P., Ross Terres, J., ... Malvar, A. (2025). Efficacy and safety of obinutuzumab in active lupus nephritis. The New England Journal of Medicine, 392(15), 1471–1483. https://doi.org/10.1056/NEJMoa2410965
  22. Fakhouri, F., Bomback, A. S., Ariceta, G., Delmas, Y., Dixon, B. P., Gale, D. P., Greenbaum, L. A., Han, S. H., Isbel, N., Le Quintrec, M., Licht, C., Mastrangelo, A., Mizuno, M., Neves de Holanda, M. I., Pickering, M. C., Remuzzi, G., Van De Kar, N., Vivarelli, M., Walker, P. D., ... Nester, C. M. (2025). Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN. The New England Journal of Medicine, 393(22), 2210–2220. https://doi.org/10.1056/NEJMoa2501510
  23. Kavanagh, D., Bomback, A. S., Vivarelli, M., Nester, C. M., Remuzzi, G., Zhao, M. H., Wong, E. K. S., Wang, Y., Krishnan, I., Schuhmann, I., Trapani, A. J., Webb, N. J. A., Meier, M., Israni, R. K., & Smith, R. J. H. (2025). Oral iptacopan therapy in patients with C3 glomerulopathy: A randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study. The Lancet, 406(10512), 1587–1598. https://doi.org/10.1016/S0140-6736(25)01148-1
  24. Arivazhagan, S., Lamech, T. M., Myvizhiselvi, M., Arumugam, V., Alavudeen, S. S., Dakshinamoorthy, S., Dineshkumar, T., Sakthirajan, R., Dhanapriya, J., Shankar, P., Padmaraj, R., Kurien, A. A., & Gopalakrishnan, N. (2022). Efficacy of corticosteroids in infection-related glomerulonephritis—A randomized controlled trial. Kidney International Reports, 7(10), 2160–2165. https://doi.org/10.1016/j.ekir.2022.07.163
  25. Barbour, S. J., Coppo, R., Zhang, H., Liu, Z. H., Suzuki, Y., Matsuzaki, K., Katafuchi, R., Er, L., Espino-Hernandez, G., Kim, S. J., Reich, H. N., Feehally, J., & Cattran, D. C. (2019). Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Internal Medicine, 179(7), 942–952. https://doi.org/10.1001/jamainternmed.2019.0600
  26. Barbour, S. J., Coppo, R., Zhang, H., Liu, Z. H., Suzuki, Y., Matsuzaki, K., Er, L., Reich, H. N., Barratt, J., & Cattran, D. C. (2022). Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney International, 102(1), 160–172. https://doi.org/10.1016/j.kint.2022.02.042
  27. Rubin, E. J. (2026). Retraction: Jayne DRW et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021;384:599-609. The New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMe2608684
  28. Rovin, B. H., Jayne, D. R. W., Sanders, J. F., Tesar, V., & Floege, J. (2026). Kidney Disease: Improving Global Outcomes (KDIGO) response to the retraction of the ADVOCATE trial publication on avacopan for the treatment of ANCA-associated vasculitis. Kidney International. Advance online publication. https://doi.org/10.1016/j.kint.2026.08.012
  29. U.S. Food and Drug Administration (FDA). (2026, April 27). CDER proposes to withdraw approval of Tavneos (avacopan) [Drug alert and statement]. https://www.fda.gov/drugs/drug-alerts-and-statements/cder-proposes-withdraw-approval-tavneos
  30. European Medicines Agency (EMA). (2026). Tavneos: Referral procedure and European Commission decision. https://www.ema.europa.eu/en/medicines/human/referrals/tavneos
  31. U.S. Food and Drug Administration (FDA). (2026, July 7). Approval letter: Atacicept, BLA 761486. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761486Orig1s000ltr.pdf
  32. Centers for Disease Control and Prevention (CDC). (2025). Clinical guidance for post-streptococcal glomerulonephritis. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/post-streptococcal-glomerulonephritis.html
  33. The Royal Children's Hospital Melbourne (RCH). (2025). Post-streptococcal glomerulonephritis (PSGN): Clinical practice guideline. https://www.rch.org.au/clinicalguide/guideline_index/Post-streptococcal_glomerulonephritis_%28PSGN%29/
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save